Review article · 2013

Development of PI3K inhibitors: lessons learned from early clinical trials

Jordi Ahnert Rodon, Rodrigo Dienstmann, Violeta Serra, Josep M. Tabernero

Nature Reviews Clinical Oncology, 10(3), 143–153 · Published 12 February 2013 · DOI 10.1038/nrclinonc.2013.10

View at the publisherCite this paper

In brief

“Development of PI3K inhibitors: lessons learned from early clinical trials” is a 2013 review article by Jordi Ahnert Rodon and 3 co-authors, published in Nature Reviews Clinical Oncology. OpenAlex counts 847 citations as of 21 November 2026, which puts it in the top 1% of works published in 2013 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
847
Most cited in
2017 (96)
Field-weighted impact
9.32
References
113
Authors
4

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Rodon, J. A., Dienstmann, R., Serra, V., & Tabernero, J. M. (2013). Development of PI3K inhibitors: lessons learned from early clinical trials. Nature Reviews Clinical Oncology, 10(3), 143–153. https://doi.org/10.1038/nrclinonc.2013.10

MLA 9

Rodon, Jordi Ahnert, et al. “Development of PI3K inhibitors: lessons learned from early clinical trials.” Nature Reviews Clinical Oncology, vol. 10, no. 3, 2013, pp. 143–153. https://doi.org/10.1038/nrclinonc.2013.10.

Chicago

Rodon, Jordi Ahnert, Rodrigo Dienstmann, Violeta Serra, and Josep M. Tabernero. 2013. “Development of PI3K inhibitors: lessons learned from early clinical trials.” Nature Reviews Clinical Oncology 10 (3): 143–153. https://doi.org/10.1038/nrclinonc.2013.10.

Harvard

Rodon, J. A. et al. (2013) ‘Development of PI3K inhibitors: lessons learned from early clinical trials’, Nature Reviews Clinical Oncology, 10(3), pp. 143–153. doi:10.1038/nrclinonc.2013.10.

IEEE

J. A. Rodon, R. Dienstmann, V. Serra, and J. M. Tabernero, “Development of PI3K inhibitors: lessons learned from early clinical trials,” Nature Reviews Clinical Oncology, vol. 10, no. 3, pp. 143–153, 2013, doi: 10.1038/nrclinonc.2013.10.

BibTeX

@article{rodon2013development,
  title     = {{Development of PI3K inhibitors: lessons learned from early clinical trials}},
  author    = {Rodon, Jordi Ahnert and Dienstmann, Rodrigo and Serra, Violeta and Tabernero, Josep M.},
  journal   = {Nature Reviews Clinical Oncology},
  year      = {2013},
  volume    = {10},
  number    = {3},
  pages     = {143--153},
  doi       = {10.1038/nrclinonc.2013.10},
  url       = {https://doi.org/10.1038/nrclinonc.2013.10}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20179696
20187070
20196161
20205555
20215555
20224141
20233333
20242828
20253131
20262424

Its field-weighted citation impact is 9.32: it has been cited 9.32 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer

  • PI3K inhibitors
  • PI3K/AKT/mTOR pathway
  • early clinical trials
  • drug safety
  • off-target effects
  • predictive biomarkers
  • drug resistance mechanisms
  • translational oncology

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Rodon, J. A., Dienstmann, R., Serra, V., & Tabernero, J. M. (2013). Development of PI3K inhibitors: lessons learned from early clinical trials. Nature Reviews Clinical Oncology, 10(3), 143–153. https://doi.org/10.1038/nrclinonc.2013.10

How many times has this paper been cited?

847 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Jordi Ahnert Rodon, Rodrigo Dienstmann, Violeta Serra, Josep M. Tabernero.

What is the DOI of this paper?

10.1038/nrclinonc.2013.10, permanently at https://doi.org/10.1038/nrclinonc.2013.10. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.